Table 1 Relationship between UBC9 protein expression and clinicopathological characteristics in patients with colorectal cancer.
From: Elevated UBC9 expression and its oncogenic role in colorectal cancer progression and chemoresistance
Clinical pathological features | UBC9 high expression | UBC9 low expression | P value |
|---|---|---|---|
Gender | Â | Â | 0.387 |
 Male | 28 | 27 |  |
 Female | 19 | 26 |  |
Age | Â | Â | 0.006 |
  ≤ 65years | 18 | 35 |  |
  > 65years | 29 | 18 |  |
Tumor size | Â | Â | 0.181 |
  ≤ 5cm | 39 | 38 |  |
  > 5cm | 8 | 15 |  |
Gross type | Â | Â | 0.504 |
 Ulcerative | 28 | 35 |  |
 Protrusive | 19 | 18 |  |
Histological type | Â | Â | 1.000 |
 Adenocarcinoma NOS | 45 | 51 |  |
 Specific type | 2 | 2 |  |
Histological grade | Â | Â | 0.483 |
 Low grade | 39 | 41 |  |
 High grade | 8 | 12 |  |
Vascular invasion | Â | Â | 0.251 |
 Present | 24 | 21 |  |
 Absent | 23 | 32 |  |
Lymph node metastasis | Â | Â | 0.020 |
 Present | 23 | 14 |  |
 Absent | 24 | 39 |  |
TNMStage | Â | Â | 0.019 |
 T1/T2 | 21 | 36 |  |
 T3/T4 | 26 | 17 |  |
Tumor mutation status | Â | Â | 0.598 |
 KRAS mutation | 32 | 15 |  |
 BRAF mutation | 2 | 3 |  |
 NRAS mutation | 1 | 4 |  |
 Wild type | 20 | 23 |  |
